ABSTRACT
Introduction Vaccination of cattle, sheep and goats with attenuated strains of Brucella is an effective measure for controlling brucellosis, although the vaccines pose risks to humans during the manufacturing process and throughout their distribution and administration to animals.
Objective The aim of this study was to review the risk posed to humans by occupational exposure to vaccine strains and the measures that should be implemented to minimize this risk.
Materials and methods This article reviewed the scientific literature indexed in PubMed up to January 31, 2023, following “the PRISMA guidelines”; special emphasis was placed on the vaccine strain used and the route of exposure.
Results Twelve primary reports were found: six included the Rev-1 strain, three the S19, and four the RB-51 strain. Rev-1 seemed to be the most virulent. The most frequent type of exposure was needle injury during administration, while exposure accidents during vaccine manufacturing were exceptional. Prolonged contact with the pathogen, lack of information and a low adherence to personal protective equipment (PPE) use in the work environment were determining factors for becoming infected. Despite strict protection measures, a percentage of vaccine manufacturing workers developed a positive serology to the vaccine strain, which may have conferred immunity.
Conclusions Brucella vaccines pose risk of contagion to humans from their production to their administration to cattle; therefore, protection measures should be extreme, and active surveillance of exposed workers should be implemented.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data that were openly available to the public before the initiation of the study. This is a systemati review of the existing literatur. The literature search was conducted on January 31, 2023, with no date or country restrictions, using the PubMed database. The search terms used were: Brucella (Rev-1 OR Rev.1 OR S19 OR S.19 OR B19 OR B-19 OR RB51) AND Human[Mesh].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
